Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-man Study of [18F]F13640
NCT03347331Phase 1Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NLX-112 (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Binding potentials. Started Apr 2018; status: completed.
02
Drugs
NLX-112
Beyond the preview
Go deeper on NCT03347331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347331.